{"public_id":"co_0381ac05a061bb6764a0fadbb8a7ca5b","status":"active","merged_into_public_id":null,"resolved_public_id":"co_0381ac05a061bb6764a0fadbb8a7ca5b","name":"Knodell necroinflammatory score","description":"A liver histology scoring system used to quantify necroinflammatory activity.","aliases":[],"types":["score"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":35926507,"title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","citation_count":1570,"url":"https://sah.borca.ai/papers/35926507"}],"claims":[{"public_id":"cl_472f4d210c4c3db2802ee3b8bf08cf14","text":"A reduction of at least two points in the Knodell necroinflammatory score occurred in 56% of patients receiving 100 mg lamivudine, 49% receiving 25 mg, and 25% receiving placebo.","corpus_id":35926507,"url":"https://sah.borca.ai/claims/cl_472f4d210c4c3db2802ee3b8bf08cf14"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_0381ac05a061bb6764a0fadbb8a7ca5b","url":"https://sah.borca.ai/concepts/co_0381ac05a061bb6764a0fadbb8a7ca5b"}